Halozyme Therapeutics, Inc. Stock News

SAN DIEGO , May 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to participate and host investor meetings at the following investor conferences. Details on the Company's participation are as follows: Event: Benchmark 2025 Healthcare House Call Virtual Conference Format: 1x...

Opdivo® is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union SAN DIEGO , May 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received European Commission (EC) approval of a new Opdivo® (nivolumab) subcutaneous formulation developed with ENHANZE®, Halozyme's proprietary recombinant h...

The top five biotech stocks today have several commonalities. Among them are strong ratings.

Halozyme Therapeutics shares tumbled Tuesday on a new Medicare approach to price negotiations for drugs that use its additive product.

Halozyme Therapeutics reported strong Q1 2025 earnings with a 35% revenue increase, 54% net income growth, and raised full-year guidance, reinforcing its status as a top biotech growth story. Key growth drivers include the ENHANZE portfolio with new blockbuster drugs, a robust clinical pipeline, and next-gen delivery systems, ensuring sustained royalty growth and competitive advantage. Despite ...

Visa has topped a buy point, while fellow S&P 500 component Insulet gapped out of a base, leading five stocks on this weekend watchlist.

Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations & Corporate Communications Helen Torley - President & Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Conference Call Participants Sadia Rahman - Wells Fargo Sean Laaman - Morgan Stanley Michael DiFiore - Evercore...

Announcing New $250M Share Repurchase  Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million; Adjusted EBITDA Increased 40% YOY to $162 million; GAAP Diluted EPS Increased 55% YOY to $0.93; non-GAAP Diluted EPS Increased 41% YOY to $1.11 1 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,2...